Crinetics Pharmaceuticals (CRNX) Preferred Stock Liabilities (2017 - 2018)
Crinetics Pharmaceuticals (CRNX) recorded quarterly Preferred Stock Liabilities of $93.0 million in Q2 2018, up 213.05% quarter-over-quarter from $29.7 million in Q4 2017.
Crinetics Pharmaceuticals (CRNX) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Crinetics Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $93.0 million for Q2 2018.
- In Q2 2018, Preferred Stock Liabilities changed N/A year-over-year to $93.0 million; the TTM figure through Jun 2018 stood at $93.0 million (changed N/A YoY), while the FY2017 annual figure was $29.7 million, up 67.42% from the prior year.
- Preferred Stock Liabilities was $93.0 million for Q2 2018 at Crinetics Pharmaceuticals, up from $29.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $93.0 million in Q2 2018 to a low of $29.7 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Crinetics Pharmaceuticals | 3.75 Bn | 3.75 Bn | 10.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 92.98 Mn |
| Dec 31, 2017 | 29.70 Mn |